Transformamos investigación en nuevas posibilidades para la vida
Algunos descubrimientos amplían
lo que sabemos, otros amplían lo que es posible.
En Ombú, trabajamos para ayudar a que ambos lleguen más lejos.
from bench
to people
Desarrollamos nuevas formas de intervenir donde hoy no las hay.
Dos formas de hacerlo
B recover
La primera terapia regenerativa para ictus isquémico.
Una nueva posibilidad allí donde hoy no existe tratamiento o donde ya no quedan opciones disponibles.
En desarrollo preclínico. Fase hacia First-in-Human.
B Living
Suplementos dietarios diseñados para acompañar y sostener tu salud a través de la innovación científica.
La ciencia de tu lado.
Línea en desarrollo. Pronto disponible.
Filosofía
Lo que nace de todos,
vuelve a todos
La ciencia es un esfuerzo colectivo.
Ningún descubrimiento ocurre en solitario. Se construye sobre conocimiento acumulado, sistemas educativos, investigación pública, colaboración y tiempo.
Por eso creemos que el conocimiento no debería quedarse donde se genera. Debería volver a quienes lo hicieron posible.
Del laboratorio a las personas
Trabajamos para que los descubrimientos lleguen más lejos.
Ombú
El descubrimiento se convierte en posibilidad.
Para las personas.
Personas
Las preguntas se convierten en conocimiento.
Educación
El conocimiento se convierte en aprendizaje.
Investigación
El aprendizaje se convierte en descubrimiento.
Ombú
El descubrimiento se convierte en posibilidad.
Para las personas.
Personas
Las preguntas se convierten en conocimiento.
Educación
El conocimiento se convierte en aprendizaje.
Investigación
El aprendizaje se convierte en descubrimiento.
Equipo
La ciencia también tiene una historia humana
Dr. Merari Tumin Chevalier
Fundadora & CEO
Ombú nació de una sencilla convicción: el conocimiento puede llegar más lejos. Tras años de investigación en biomateriales, Merari se propuso convertir la ciencia en acción.
Un proyecto construido en equipo
Reunimos perfiles científicos, clínicos y estratégicos para construir soluciones con impacto real.
Equipo
Janice Chantal Chevalier
CFO (Chief Financial Officer)
Dr. José Martinez Orgado
CMO (Chief Medical Officer)
Antonia Lorca Olivares
Junior Business Development Associate
Dr. Flavia Bern Barbehito
Junior Regulatory Affairs Associate
Consejo Asesor Científico
Prof. Abhay Pandit
Prof. José Carlos Rodríguez Cabello
Prof. Matilde Alonso Rodrigo
Contacto
Sigamos la conversación
La ciencia avanza mejor cuando más personas forman parte de ella. Si quieres conocer nuestro trabajo, explorar colaboraciones o simplemente seguir de cerca lo que estamos construyendo, estaremos encantados de escucharte.
| Teléfono | +34 655 996 750 |
|---|---|
| info@ombues.com | |
| Ombú |
Dr. Merari Tumin Chevalier, PhD, MBA
Founder & CEO
A chemist and PhD in Materials Science specializing in biomaerials, with training in business administration, Merari built her career developing nanotherapies and polymeric hydrogels for tissue regeneration, with an emphasis on their application in cardiovascular diseases. Her path took her from international academic research to technology entrepreneurship. She leads Ombú by combining scientific rigor with business vision to advance health solutions, with a focus on B recover, the first regenerative therapy aimed at all survivors of ischemic stroke.
Janice Chantal Chevalier
CFO (Chief Financial Officer)
She studied Economics and Commercialization, with additional training in international business and business management. She brings solid experience in financial management, commercial operations, foreign trade, and innovation. Her approach combines operational efficiency with a strong sensitivity to social impact and environmental sustainability, aligning with Ombú's vision of building science that reaches the market with purpose.
Dr. José Martinez Orgado
CMO (Chief Medical Officer)
Head of Neonatology at Hospital Clínico San Carlos and Associate Professor of Pediatrics at UCM, Dr. Martínez Orgado brings extensive clinical and research experience in neonatal neurology and neuroprotection, with particular expertise in translating novel therapeutics from bench to bedside. His clinical authority in neonatal, adult stroke and brain injury anchors Ombú's regulatory and translational strategy, ensuring B recover's development stays grounded in real-world patient need.
Antonia Lorca Olivares
Junior Business Development Associate
A graduate in Business Administration and Management with a Master's degree in Marketing, Antonia combines analytical rigor, creativity, and strategic vision in business development. She stands out for her communication skills, her ability to manage complex processes, and her passion for bringing visibility to solutions that deliver real value to society. She drives the growth of Ombú's various business units with a hybrid perspective that bridges commercial strategy and market trends.
Dr. Flavia Bern Barbehito
Junior Regulatory Affairs Associate
A medical doctor with a Master's degree in the Pharmaceutical Industry focused on pharmacovigilance, compliance, and regulatory affairs, Flavia combines her clinical training with a genuine curiosity for research and scientific development, bringing a rigorous perspective on the safety and quality of the health solutions Ombú offers. Her commitment to agile problem-solving in the face of uncertainty makes her a natural bridge between science, regulation, and the patient. Her work helps ensure that Ombú meets the highest regulatory and safety standards.
Prof. Abhay Pandit
Scientific Advisory Board
Professor Abhay Pandit is the Director of CÚRAM, Research Ireland Centre for Medical Devices, and an Established Professor of Biomaterials at the University of Galway. His research focuses on developing advanced biomaterial platforms for targeted delivery of biomolecules to aid molecular and cellular repair. He is particularly interested in optimizing biomaterial substrates for glycomodulating biomolecules to treat rare eye diseases, aiming to restore cell physiology, immune balance, vascularization, neural function, and signaling in corneal pathology.
His work has contributed to the development of biomaterial platforms for neural, musculoskeletal, and cardiovascular applications, many of which have been validated for clinical use. He has published over 400 peer-reviewed papers leading to a h-index of 70, filed numerous patents, and licensed four technologies to medical device companies. Prof. Pandit has also secured €90M in research funding, coordinated four EU grants, and received multiple prestigious awards, including fellowships from AIMBE, the International Union of Societies for Biomaterials Science and Engineering, and the Tissue Engineering and Regenerative Medicine International Society.
Prof. José Carlos Rodríguez Cabello
Scientific Advisory Board
Dr. Rodríguez-Cabello is a Full Professor at the University of Valladolid, Spain, specializing in polymer physics and biomaterials science. He founded BIOFORGE in 1997, now a world-leading research group in recombinamers. His research focuses on biofunctional, smart, and customized protein polymers for advanced biomedical applications.
He has authored 200 peer-reviewed papers, 13 book chapters, 9 patents, leading to a h-index of 49. He has supervised 23 PhD students, 20 MSc students, and 7 postdoctoral fellows. Prof. Rodríguez-Cabello has coordinated numerous National and European research projects, securing over €8 million in funding over the last decade. He has been actively involved in scientific societies, journal editorial boards, and international conference committees, delivering 38 invited/keynote/plenary talks at major scientific events, including SIBB, TERMIS, ESB, and the World Polymer Congress.
Prof. Matilde Alonso Rodrigo
Scientific Advisory Board
Dr. Matilde Alonso Rodrigo, PhD in Chemical Sciences from the University of Valladolid, is a Full Professor at the University School of the University of Valladolid. She is a founding member of the Bioforge Group, recognized as a Group of Excellence by the Regional Government of Castilla y León. Her research focuses on recombinant elastin-like polymers, with more than 100 indexed publications leading to an h-index of 38 and six patents (three PCTs).
She has supervised many doctoral theses, receiving prestigious awards. Dr. Alonso Rodrigo has participated in 40+ research projects, including EU-funded programs like BioPolySurf (FP6) and Elastislet (H2020), and has led 12 projects funded by national, regional, and industry collaborations. She is also a co-founder of TECHNICAL PROTEINS NANOBIOTECHNOLOGY S.L., a University of Valladolid spin-off established in 2010.